Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).
Christopher C ButlerChris EllisPedro M FolegattiHannah SwayzeJulie AllenLouise BusseyDuncan BellamyAlison LawrieElizabeth Eagling-VoseLy-Mee YuMilensu ShanyindeCatherine MairAmy L FlaxmanKatie J EwerSarah GilbertThomas G Evansnull On Behalf Of The Invictus InvestigatorsPublished in: Vaccines (2021)
The MVA-NP+M1 vaccine is well tolerated in those aged 65 years and over. Larger trials would be needed to determine potential efficacy.